TrialHaematologica2025

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.

Salomon Manier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.